Organoids Market Size and Growth 2031

The organoids market size is projected to reach US$ 15.01 billion by 2031 from US$ 3.03 billion in 2023. The market is expected to register a CAGR of 22.3% in 2023–2031. The integration of artificial intelligence is likely to act as one of the key trends in the organoids market in the future.

Organoids Market Analysis

Factors contributing to the organoids market growth include the rising demand for novel drug screening services, and an upsurge in the popularity of customized medications. However, the dearth of skilled professionals and stringent safety regulations hamper the market growth.

Organoids Market Overview

Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids (PDOs) opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently, and avoid costly and time-consuming setbacks in clinical trials. The organoid market is experiencing rapid growth owing to the increasing demand for innovative screening services.

Customize This Report To Suit Your Requirement

You will get customization on any report - free of charge - including parts of this report, or country-level analysis, Excel Data pack, as well as avail great offers and discounts for start-ups & universities

Get FREE CUSTOMIZATION

Organoids Market: Strategic Insights

• Get Top Key Market Trends of this report.
  This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.

Free Sample PDF

Organoids Market Drivers and Opportunities

Surge in Popularity of Personalized Drugs Favors Organoids Market

Personalized or precision medicine is the study of practices or drugs tailored to the individual patient based on the projected response or disease risk. According to a study released by the Personalized Medicine Coalition (PMC), the share of personalized medication approvals in total FDA approvals for new molecular entities rose from 5% in 2005 to over 25% in 2016. Further, 73% of compounds in the pipeline are potential oncological candidates, and 42% have the potential to be personalized therapies. Biopharmaceutical companies have virtually doubled their R&D investments in personalized pharmaceuticals. Further, in the coming years, this spending is expected to surge by 33%. Moreover, researchers in the field of biopharmaceuticals anticipate a 69% rise in the creation of customized medications during the said period. As per the most recent study published in the PMC in 2021, the number of customized medications available in the US market has jumped up from 132 in 2016 to 286 in 2020. The information was produced by tracking the PMC's numbers for personalized medication since 2008. The use of organoids to produce customized medication regimens holds significant prospects for enhancing patient care. With their active efforts to promote and raise awareness of precision medicine, pharmacists play a crucial role in driving up demand for customized medications. According to a recent published in one of the NCBI journals in 2021, more than 50% of consumers preferred to buy customized goods or services. These stats indicate the build up of a conducive environment for the growth of the organoids market.

Key Developments by Companies to Create Opportunities for Organoids Market Growth

The progress of the healthcare sector has led to a rise in the demand for organoids across the world. This increased demand contributes to new product developments, acquisitions, partnerships, product launches, and approvals on a global level. Major market players are involved in activities to ensure the innovation and development of efficient services and products. A few of the recent key developments are listed below:

• In June 2024, Molecular Devices, LLC. formally opened its purpose-built facility in Cardiff, UK. The multimillion-pound facility was designed to accommodate the exclusive bioprocess workflow and innovative bioreactor technology of the business, allowing for the large-scale, quality-controlled production of PDOs. Substantial amounts of repeatable PDOs that are 3D-ready are available as a custom service and are cryopreserved in a manner that is ready for analysis. Researchers can defrost, plate, and use these products when needed.
• In January 2024, HUB Organoids (HUB) launched IntegriGut Screen services for the global market. This screening service employs IBD PDO monolayers to aid in the development of novel IBD therapies by ensuring the availability of high-quality human data on epithelial barrier function.
• In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications.
• In July 2023, Molecular Devices launched a custom organoid line expansion service with unique bioprocess technology for high-throughput applications.
• In February 2023, Molecular Devices, LLC., and HUB Organoids (HUB) announced a strategic collaboration to contribute to the continued development of next-generation 3D biology technologies that enable step-change reduction in preclinical to clinical drug attrition.

Such key developments, launches, and strategic collaborations create ample opportunities for the organoid market growth.

Organoids Market Report Segmentation Analysis

Key segments that contributed to the derivation of the organoids market analysis are product, application, source, and manufacturing.

• Based on type, the organoids market is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the market in 2023, and it is further anticipated to register the highest CAGR during the forecast period.
• By application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology disease segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023–2031.
• Based on source, the organoids market is divided into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2023. The pluripotent stem cells segment is anticipated to register a higher CAGR during the forecast period.
• The organoids market, by offerings, is segregated into instruments, consumables, and services. Instruments segment is further divided into devices and equipment. On the other hand, consumables segment is divided into sensors and others. The consumables segment held the largest share in the organoids market in 2023.
• The organoids market, by method, is segregated into hanging drop, micropatterned plates, ultralow attachment plates, microdroplet/emulsion, and others. The hanging drop segment held the largest share in the organoids market in 2023.

Organoids Market Share Analysis by Geography

The geographic scope of the organoids market report is mainly divided into five regions: North America, Asia Pacific, Europe, and the Middle East & Africa.

North America dominates the organoids market. Market players in the US are focusing on organic growth strategies to strengthen their foothold. In February 2023, Molecular Devices, LLC. and HUB Organoids (HUB) announced a strategic collaboration to continue the development of next-generation 3D biology technologies that drive step-change reduction in preclinical to clinical drug attrition. Further, increasing research and development activities, rising demand for tissue engineering and organ transplantation, and a high rate of organoid adoption are driving the organoid market in the country. Organoids have the potential to overcome several previous limitations associated with biomedical research studies, with a high focus on making mechanistic insights on human development available for researchers, producing accurate models of human disease, and generating patient-matched tissue sources for regenerative medicine. Asia Pacific is anticipated to record the highest CAGR during 2023–2031.

Organoids Market Regional Insights

The regional trends and factors influencing the Organoids Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Organoids Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.

Organoids Market Report Scope

Organoids Market Players Density: Understanding Its Impact on Business Dynamics

The Organoids Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.

Major Companies operating in the Organoids Market are:

1. Sino Biological Inc.
2. Eurofins Scientific SE
3. Molecular Devices, LLC.
4. InSphero
5. Cyprio InnoSer
6. LABTOO

Disclaimer: The companies listed above are not ranked in any particular order.

Organoids Market News and Recent Developments

The organoids market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the market are listed below:

• InSphero, a biotech company, signed a partnership agreement with Genome Biologics, Frankfurt. In this partnership, InSphero will receive the exclusive global rights to commercialize Genome Biologics' 3D Cardiac Organoid Platform. The platform provides accurate, scalable, and disease-specific organoid models for creating novel treatments, placing it at the forefront of heart disease research. (InSphero, Press Release, May 2024)

Organoids Market Report Coverage and Deliverables

The "Organoids Market Size and Forecast (2021–2031)" report provides a detailed analysis of the market covering below areas:

• Organoids market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
• Organoids market trends as well as market dynamics such as drivers, restraints, and key opportunities
• Detailed PEST/Porter's Five Forces and SWOT analysis
• Organoids market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments.
• Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the Organoids market
• Detailed company profiles